Imaging Groups Disappointed By CMS’ Final Beta Amyloid PET NCD
This article was originally published in The Gray Sheet
Executive Summary
Agency’s final national coverage determination for beta amyloid positron emission tomography to diagnose dementia confirms that Medicare will cover the procedure only in clinical trials. On the positive side, it may offer a bit more flexibility in trial design.